Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence

#2107

Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking

Aim(s): The aim was to provide real-life activity/efficacy/safety data on CB-ET in this setting

Materials and methods: Records of pts with advanced EP-PD-NEC (06/09-04/17) treated with CB-ET were retrospectively reviewed

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Frizziero M

Authors: Frizziero M, Lamarca A, Kordatou Z, Barriuso J, Nuttall C,

Keywords: carboplatin-etoposide, poorly-differentiated extra-pulmonary neuroendocrine carcinoma, activity, efficacy, safety,

To read the full abstract, please log into your ENETS Member account.